Clinical Trials Browser

Phase 1 × Urinary Bladder Neoplasms × durvalumab × Clear all

NCT03258593 2026-03-17

Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)

Phase 1 Completed

15 enrolled 21 charts

Urinary Bladder Neoplasms, Carcinoma in Situ

NCT06963346 2026-03-09

Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents

Phase 1 Suspended

Urinary Bladder Neoplasms

NCT03983954 2025-11-28

Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.

Phase 1 Active not recruiting

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT03773666 2022-09-13

A Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2)

Phase 1 Completed

Urinary Bladder Neoplasms

NCT04073160 2020-07-07

TRIO Bladder

Phase 1 Withdrawn

Urinary Bladder Neoplasms